Benda Anticipates 2008 Approval In India For Gene Therapy Product
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China-Based Benda Pharmaceuticals anticipates 2008 approval from India's Central Drugs Control Organization for its gene therapy product Gendicine for treatment of head and neck cancer. The company filed its application for the recombinant human Ad-p53 injection in November
You may also be interested in...
Sanofi-Aventis China R&D Head Frank Jiang On Forming A Fully Integrated Drug R&D Platform In China: An Interview With Pharmasia News
Sanofi-Aventis opened its doors in Shanghai in June 2005 with its China Clinical Research Unit, established to conduct high-quality clinical trials that would pass regulatory muster worldwide. The company recently expanded its R&D presence in the country by broadening its activities. Sanofi VP and China R&D Head Frank Jiang talked to PharmAsia News' Shanghai bureau about Sanofi's R&D strategy in China.
Sanofi-Aventis China R&D Head Frank Jiang On Forming A Fully Integrated Drug R&D Platform In China: An Interview With Pharmasia News
Sanofi-Aventis opened its doors in Shanghai in June 2005 with its China Clinical Research Unit, established to conduct high-quality clinical trials that would pass regulatory muster worldwide. The company recently expanded its R&D presence in the country by broadening its activities. Sanofi VP and China R&D Head Frank Jiang talked to PharmAsia News' Shanghai bureau about Sanofi's R&D strategy in China.
Benda’s Jiangling Plant Gets Production Approval
SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22